Tue, 14 Oct 2014 11:15:00 GMT ~ Aethlon Medical Announces First Treatment of an Ebola Patient
[PR Newswire] - SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. The largest ebola virus epidemic in history is now spreading on a global basis with more than 4,000 deaths being reported by the WHO.
Tue, 07 Oct 2014 13:00:00 GMT ~ SeeThruEquity Issues Company Note on Aethlon Medical and Increase Target Price to $0.52
[Accesswire] - Company Announces Collaboration with Boston University CTE Center and Expanded Hemopurifier Clinical Studies New York, NY / ACCESSWIRE / October 7, 2014 / SeeThruEquity, a leading independent equity research ...
Tue, 07 Oct 2014 12:30:00 GMT ~ Aethlon Medical, Inc. – “A Pivotal Moment That Changed the NFL and CTE Research”
[Accesswire] - New York, NY / October 7, 2014 / Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman and CEO, James Joyce. TheChairmansBlog.com ...
Link: http://www.otcmarkets.com/stock/AEMD/company-info Ticker: $AEMD OTC Market Place: OTCQB CIK code: 0000882291 Company name: Aethlon Medical, Inc. Company website: http://www.aethlonmedical.com Incorporated In: NV, USA
Business Description: The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats.Less >>
$AEMD share structure
## source: otcmarkets.com
Market Value: $53,524,821 a/o Oct 21, 2014 Shares Outstanding: 261,096,690 a/o Aug 12, 2014 Float: Not Available Authorized Shares: Not Available Par Value: 0.001
$AEMD extra dd links
Company name: Aethlon Medical, Inc. Company website: http://www.aethlonmedical.com